- Home
- MHLD vs BDTX Comparison
MHLD vs BDTX Comparison
Compare MHLD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHLD
- BDTX
- Stock Information
- Founded
- MHLD 2007
- BDTX 2014
- Country
- MHLD Bermuda
- BDTX United States
- Employees
- MHLD N/A
- BDTX N/A
- Industry
- MHLD Property-Casualty Insurers
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MHLD Finance
- BDTX Health Care
- Exchange
- MHLD Nasdaq
- BDTX Nasdaq
- Market Cap
- MHLD 96.4M
- BDTX 96.9M
- IPO Year
- MHLD 2008
- BDTX 2020
- Fundamental
- Price
- MHLD $0.59
- BDTX $1.57
- Analyst Decision
- MHLD
- BDTX Strong Buy
- Analyst Count
- MHLD 0
- BDTX 5
- Target Price
- MHLD N/A
- BDTX $15.60
- AVG Volume (30 Days)
- MHLD 165.4K
- BDTX 8.3M
- Earning Date
- MHLD 03-10-2025
- BDTX 03-06-2025
- Dividend Yield
- MHLD N/A
- BDTX N/A
- EPS Growth
- MHLD N/A
- BDTX N/A
- EPS
- MHLD N/A
- BDTX N/A
- Revenue
- MHLD $56,436,000.00
- BDTX N/A
- Revenue This Year
- MHLD N/A
- BDTX N/A
- Revenue Next Year
- MHLD N/A
- BDTX N/A
- P/E Ratio
- MHLD N/A
- BDTX N/A
- Revenue Growth
- MHLD N/A
- BDTX N/A
- 52 Week Low
- MHLD $0.57
- BDTX $1.51
- 52 Week High
- MHLD $2.27
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- MHLD 33.88
- BDTX 37.67
- Support Level
- MHLD $0.67
- BDTX $1.55
- Resistance Level
- MHLD $0.75
- BDTX $1.84
- Average True Range (ATR)
- MHLD 0.06
- BDTX 0.22
- MACD
- MHLD -0.01
- BDTX 0.00
- Stochastic Oscillator
- MHLD 0.00
- BDTX 5.88
About MHLD Maiden Holdings Ltd.
Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.